Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03493685|
Recruitment Status : Active, not recruiting
First Posted : April 10, 2018
Last Update Posted : December 14, 2020
|Condition or disease||Intervention/treatment||Phase|
|Focal Segmental Glomerulosclerosis||Drug: sparsentan Drug: Irbesartan||Phase 3|
This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 300 study centers, globally. The investigational drug (sparsentan) is a dual-acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. Patients who meet eligibility criteria will require washout from renin-angiotensin-aldosterone system (RAAS) blockers, if applicable prior to their first dose of study drug.
Patients will be randomly assigned in a 1:1 ratio to receive either sparsentan or active control (irbesartan).
After completing the double-blind portion of the study, patients may participate in the open-label extension for treatment with sparsentan if they meet eligibility criteria.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS|
|Actual Study Start Date :||March 29, 2018|
|Estimated Primary Completion Date :||June 2022|
|Estimated Study Completion Date :||December 2022|
Experimental: sparsentan for double-blind and open-label extension
Sparsentan will be administered as a single oral morning dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
Other Name: RE-021
Active Comparator: Irbesartan
Irbesartan will be administered as a single oral morning dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
target dose of 300 mg daily
Other Name: Irbesartan Tablets USP
- Slope of estimated glomerular filtration rate (eGFR) [ Time Frame: Week 6 to Week 108 ]The slope of estimated glomerular filtration rate (eGFR) from Week 6 to Week 108.
- Proportion of patients achieving a UP/C ≤1.5 g/g and a >40% reduction [ Time Frame: Week 36 ]Proportion of patients achieving a UP/C ≤1.5 g/g and a >40% reduction from baseline in UP/C at Week 36
- Percentage Change in eGFR [ Time Frame: Week 108 ]Percentage change from 6 weeks post randomization at Week 108
- Percentage Change in eGFR from baseline [ Time Frame: Week 112 ]Percentage change in eGFR from baseline to 4 weeks post-cessation of treatment at Week 112
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03493685
|Study Director:||Radko Komers, MD, PhD||Travere Therapeutics, Inc.|